author-photo

Yuhong Zhang

Takeda Pharmaceutical Company

6

Papers

20

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
552 SUMOylation inhibitor TAK-981 activates NK cells and macrophages via Type I interferon signaling and shows synergistic activity in combination with rituximab and daratumumab in preclinical models

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (2)
A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara)

2019 Blood
Show All
- Source
- Cite
- Save
Citations (4)